Cases / 2024-08-01-D-1097
completed2024-08-01D series

Efbemalenograstim alfa

Febrile Neutropenie infolge Chemotherapie

Open official case page ↗
Brand
Ryzneuta
Manufacturer
Evive Biotech

G-BA action

final resolution

2024-10-02

Arzneimittel-Richtlinie/Anlagen XII, IX und X: Koloniestimulierende Faktoren, pegyliert, Gruppe 1, in Stufe 2

Evidence-checked summary

The G-BA issued a final resolution on 2024-10-02. The official page states that it took effect as follows: 02.10.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V, Anlage IX: Festbetragsgruppenbildung, Anlage X: Aktualisierung von Vergleichsgrößen as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

0 hearing

No official oral hearing is attached to this case.

IQWiG comparison

Assessment record versus G-BA action

0 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.

G-BA decisions

Distinct actions and documents

1 decision

2024-10-02

final resolution

Arzneimittel-Richtlinie/Anlagen XII, IX und X: Koloniestimulierende Faktoren, pegyliert, Gruppe 1, in Stufe 2

The G-BA issued a final resolution on 2024-10-02. The official page states that it took effect as follows: 02.10.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V, Anlage IX: Festbetragsgruppenbildung, Anlage X: Aktualisierung von Vergleichsgrößen as the normative target.

2 official documents · 3 cited claims

Official sources

Case document package

3 source
Generic graph relations · 1